Hope Care has raised €6 million to expand its regulated remote patient-monitoring platform across European healthcare systems, giving the Portuguese company more capital for a form of digital health that succeeds only when software, medical devices, clinicians, and existing services can work together reliably.

The Series A was led by Iberis Capital, with Vieira de Matos – VDM Capital and existing shareholder Buenavista Equity Partners also participating. Hope Care plans to deepen its commercial and operational capacity while expanding into additional European markets.

Its OpMA platform brings together readings from medical devices, patient-reported information, and clinical workflows so healthcare teams can monitor people outside hospitals and respond when their condition changes. The model is intended to support several chronic conditions rather than operating as a single-purpose connected device.

That distinction matters because remote monitoring has been technically possible for years, while routine deployment remains difficult. Hospitals and other healthcare providers still need data they can trust, workable alert thresholds, clear clinical responsibility, integration with existing systems, and enough staff capacity to respond when a platform identifies a patient requiring attention.

Expansion means adapting to different systems

Hope Care already operates programmes in Portugal and France, while a project is underway in Switzerland. The company has established a German subsidiary at Medical Valley in Erlangen and expects its first German deployment to begin in October, while activity to establish a Romanian presence is also planned.

Those markets differ substantially in reimbursement, procurement, data infrastructure, clinical organisation, and the relationship between hospitals, primary care, and community services. A software platform may be technically portable, but the service built around it usually requires local adaptation before it can become part of routine care.

Hope Care says its technology is already used by 15 Local Health Units in Portugal, covering around 45% of registered users of the country’s National Health Service, as well as regional health services in Madeira and the Azores. Those figures are company-reported, but they suggest the platform has moved beyond isolated pilots in its home market.

International expansion raises a higher hurdle because procurement routes and clinical responsibilities change between countries. A system that fits Portugal’s service model still has to prove that healthcare organisations elsewhere can integrate it without creating additional administrative work or duplicating existing technology.

Monitoring has to change clinical work

The economic case for remote patient monitoring usually rests on identifying deterioration earlier and reducing avoidable hospital use, particularly among people living with chronic conditions. Connected devices can provide regular information outside the clinic, but the data creates value only when a healthcare team can interpret it and intervene at the right point.

That makes workflow design as important as the devices themselves. A blood-pressure reading, oxygen measurement, or patient questionnaire may be clinically useful, yet repeated low-value alerts can increase workload if the system is poorly configured or responsibility for escalation remains unclear.

Hope Care says a 12-month analysis involving 43 people with chronic obstructive pulmonary disease produced substantial reductions in hospital days and emergency visits, alongside estimated savings of €4,811 per patient each year. The programme was limited and the results are company-reported, so they should not be treated as evidence that the same economics will automatically transfer across larger populations or different healthcare systems.

They do illustrate the type of proof remote-care providers increasingly need to produce. Digital-health markets have accumulated large numbers of pilots in which technology worked technically but failed to become routine because integration costs, staffing, procurement, or weak evidence prevented wider adoption.

Regulation is part of deployment

Hope Care presents OpMA as a Class IIb medical-device platform under the EU Medical Device Regulation. That status places the product in a different category from general wellness software because systems supporting clinical decisions face formal requirements around quality, risk, and post-market controls.

Regulatory compliance removes only one barrier to expansion. Healthcare organisations still need to establish whether the platform fits local clinical practice, can exchange information with existing systems, meets security and data-protection requirements, and offers enough operational value to justify procurement.

The €6 million round therefore finances a service-integration problem rather than a simple software rollout. Germany, Romania, Switzerland, and France give Hope Care access to much larger markets than Portugal alone, but each new deployment must adapt to the way care is organised and paid for locally.

The strongest evidence will come from what happens after those programmes mature: whether clinicians can safely manage larger patient populations, whether alerts lead to useful intervention rather than additional workload, and whether any reduction in acute care survives beyond small studies. Remote monitoring does not become infrastructure when the devices connect; it becomes infrastructure when the surrounding health service can rely on the system every day.